👂
Ménière’s Disease — Assessment & Management UK primary care pathway · RCGP SCA preparation · vertigo + fluctuating hearing loss
Progress 0 / 9
The full reasoning pathway — recognise the triad of episodic vertigo, fluctuating hearing loss and tinnitus, confirm with audiology, and exclude central and other causes. Treat acute and preventive, advise, and safety-net.StartDecisionInvestigateActionReferStop / Admit
PresentationSuspected Ménière disease
Recurrent spontaneous vertigo (20 min–12 h) + fluctuating sensorineural hearing loss + tinnitus/aural fullness. Audiology.
Step 1 · Safety — central / red-flag featuresCentral or red-flag features?
Persistent/atypical vertigo, focal neurology, unilateral progressive hearing loss → exclude central cause / acoustic neuroma.
YES
Stop · EscalateInvestigate / refer
Central features → imaging/neurology. Asymmetric SNHL → MRI (acoustic neuroma).
NO
AssessBy pattern
History + examination localise the cause.
Step 7 · common causes & management
Acute attack
Management
Vestibular sedative (prochlorperazine) short-term; antiemetic; reassurance.
Prevention
Long-term
Reduce salt/caffeine/alcohol; betahistine; ENT-led options (intratympanic) if refractory.
Confirm + monitor
Audiology
Serial audiometry confirms fluctuating SNHL; document.
Step 6 · ReferEscalation
ENT / audiovestibular for diagnosis confirmation and management; MRI if asymmetric hearing loss to exclude acoustic neuroma. Advise on DVLA (sudden vertigo).
Step 8 · lifestyle & trigger control
Step 8 · Lifestyle & trigger controlReduce attack frequency
Low-salt diet and reduce caffeine, alcohol and (where relevant) chocolate/tobacco; good hydration and regular meals/sleep; stress reduction. Vestibular rehabilitation for chronic imbalance between attacks; hearing aids for established hearing loss; tinnitus support. Betahistine for prevention as directed.
Step 9 · review & safety-net (DVLA)
Step 9 · Review, safety-net & drivingMonitor hearing; escalate red flags
Serial audiometry to confirm/monitor fluctuating SNHL and document attacks; review preventive treatment response. MRI for unilateral progressive or asymmetric hearing loss (acoustic neuroma) before attributing to Ménière. DVLA: must stop driving and notify if liable to sudden, disabling vertigo — document the advice. Urgent reassessment for new neurology.
⚠️ Ménière needs the full triad and audiometric confirmation — and unilateral progressive hearing loss should prompt MRI to exclude an acoustic neuroma before attributing it to Ménière.
1
Safety

Exclude Sinister & Central Causes of Audiovestibular Symptoms

Before labelling episodic vertigo + hearing loss as Ménière’s, exclude the dangerous and the specifically-treatable causes of unilateral audiovestibular dysfunction.

Sudden sensorineural hearing loss Rapid unilateral SNHL (over hours–3 days) → same-day ENT for steroids within 72h — an otological emergency, not Ménière’s.
Central vertigo / stroke Vertical or direction-changing nystagmus, focal neurology, ataxia, diplopia → 999.
Acoustic neuroma (vestibular schwannoma) Progressive unilateral hearing loss/tinnitus ± imbalance → ENT + MRI IAM to exclude.
Ramsay Hunt Vertigo + ear pain + vesicles ± facial palsy → same-day antivirals + steroids.
Bacterial labyrinthitis / cholesteatoma Otalgia, discharge, systemic upset, attic crust → urgent ENT.
Cardiac / drug causes Pre-syncope, arrhythmia, ototoxic drugs (aminoglycosides, loop diuretics, cisplatin) — review and exclude.
Unilateral audiovestibular symptoms have several serious mimics that must be excluded before diagnosing Ménière’s: sudden SNHL is time-critical (steroids within 72h), progressive unilateral hearing loss/tinnitus mandates MRI to exclude vestibular schwannoma, and central signs point to stroke. Ménière’s is, in part, a diagnosis of exclusion.
2
Diagnose

History — The Ménière’s Triad & Attack Pattern

Ménière’s is defined by recurrent spontaneous vertigo with fluctuating cochlear symptoms; the duration of attacks is a key discriminator.

Vertigo
Spontaneous (not positional) rotational vertigo lasting 20 minutes to 12 hours (rarely up to 24h). Recurrent, clustering then remitting.
Fluctuating hearing loss
Low-frequency sensorineural loss, typically unilateral, fluctuating early then progressive over years.
Tinnitus & aural fullness
Unilateral tinnitus and a sensation of pressure/fullness in the affected ear, often heralding attacks.
Associated
Nausea/vomiting, imbalance for hours–days after; “drop attacks” (Tumarkin) in some.
Diagnostic criteria
≥2 spontaneous vertigo episodes ≥20 min, audiometrically-confirmed low/mid-frequency SNHL in the affected ear, plus fluctuating aural symptoms (Bárány/AAO-HNS criteria).
Differentials
Vestibular migraine (headache/photophobia, migraine history), BPPV (brief positional), neuritis (single prolonged attack, no hearing loss).
The 20-minute-to-12-hour attack duration with fluctuating low-frequency hearing loss, tinnitus and aural fullness defines Ménière’s and separates it from BPPV (seconds), vestibular neuritis (days, no hearing loss) and vestibular migraine (variable, with migrainous features). Vestibular migraine is the most common and most under-recognised mimic.
3
Diagnose

Examination

Examination is often normal between attacks; its role is to support the diagnosis and exclude alternatives.

Otoscopy
Normal in Ménière’s; exclude middle-ear disease/cholesteatoma.
Tuning forks / hearing
Weber lateralises to the better ear; Rinne positive bilaterally → sensorineural pattern.
Nystagmus
During an attack: horizontal nystagmus (peripheral). Vertical/direction-changing → central, reconsider.
HINTS (acute continuous)
Use only in acute sustained vertigo to separate peripheral from central.
Cranial nerves / cerebellar
Normal between attacks; abnormal signs warrant central workup.
Cardiovascular
Lying/standing BP and pulse to exclude orthostatic/arrhythmic dizziness.
Between attacks the examination is typically unremarkable, so a normal exam does not exclude Ménière’s. The purpose is to demonstrate a sensorineural, peripheral pattern and to exclude central signs, middle-ear disease and cardiovascular causes of dizziness.
4
Diagnose

Investigations

Confirm sensorineural hearing loss with audiometry and exclude retrocochlear pathology where indicated.

Pure-tone audiometry Key test
Documents the low/mid-frequency SNHL and its fluctuation; central to formal diagnosis and monitoring.
MRI internal auditory meati Exclude schwannoma
For unilateral/asymmetrical SNHL or tinnitus to exclude vestibular schwannoma and central pathology.
Bloods
FBC, glucose/HbA1c, TFTs, U&E; consider autoimmune/syphilis screen in atypical/bilateral disease.
Specialist vestibular tests
Electrocochleography, VEMP, caloric testing — ENT/audiovestibular led, not primary care.
Not routinely useful
CT head; routine bloods rarely diagnostic but help exclude contributors.
Audiometry is the cornerstone investigation, objectively confirming the characteristic fluctuating low-frequency sensorineural loss and tracking progression. MRI of the internal auditory meati is essential whenever hearing loss or tinnitus is unilateral/asymmetrical, because vestibular schwannoma can mimic early Ménière’s.
5
Treat

Management — Acute Attacks & Prophylaxis

Treat acute attacks symptomatically and reduce attack frequency with lifestyle and prophylaxis; involve ENT for diagnosis and refractory disease.

Acute attackVestibular sedatives, short-term — prochlorperazine (buccal/oral/IM) or an antihistamine (cyclizine/cinnarizine) for severe vertigo and vomiting; use only for the attack, not long-term.
LifestyleLow-salt diet and reduced caffeine/alcohol; address triggers; smoking cessation. First-line preventive approach.
ProphylaxisBetahistine 16 mg TDS (up to 48 mg/day) to reduce frequency/severity (widely used in UK; evidence modest). Trial 3–6 months.
Specialist add-onDiuretics (e.g. thiazide) used by some specialists; vestibular rehabilitation for chronic imbalance.
Refractory (ENT)Intratympanic steroids, intratympanic gentamicin (ablative), or surgery (e.g. endolymphatic sac, labyrinthectomy) for disabling, treatment-resistant disease.
Management has two arms: aborting the acute attack with short-term vestibular sedatives and reducing attack frequency through salt restriction and betahistine. Long-term vestibular sedatives impair central compensation and should be avoided. Refractory disease is escalated to ENT for intratympanic therapy or surgery.
6
Refer

Referral Pathways

Ménière’s should be confirmed and supervised by ENT/audiovestibular services; manage attacks and prophylaxis in primary care.

Same-day ENT
Sudden sensorineural hearing loss with vertigo, Ramsay Hunt, suspected cholesteatoma/bacterial labyrinthitis.
ENT + MRI
Unilateral/asymmetrical hearing loss or tinnitus to exclude vestibular schwannoma; to confirm the diagnosis.
ENT / audiovestibular
Diagnostic confirmation, audiometry, and management of refractory disease (intratympanic therapy, surgery).
Neurology
Suspected vestibular migraine or central cause.
Vestibular physiotherapy
Chronic imbalance/unsteadiness between attacks.
Primary care manage
Acute attacks, lifestyle, betahistine trial, monitoring, and DVLA advice.
Because Ménière’s overlaps with serious mimics, diagnosis is best confirmed in ENT with audiometry and (for asymmetrical loss) MRI. Primary care retains an important ongoing role in attack management, prophylaxis, psychological support and statutory driving advice.
7
Lifestyle

Lifestyle, Driving & Support

Low-salt diet Cornerstone preventive measure; reduce processed foods; aim for a consistent low-sodium intake.
Trigger reduction Limit caffeine, alcohol; manage stress and sleep; stop smoking.
DVLA Ménière’s is notifiable — patients must inform the DVLA and must not drive during attacks or if liable to sudden disabling vertigo. Advise explicitly and document.
Safety Avoid heights/ladders/swimming alone during active disease; plan for sudden attacks.
Hearing support Audiology input, hearing aids for progressive loss; tinnitus support strategies.
Psychological & peer support Anxiety/depression are common; signpost to the Ménière’s Society and offer mental-health support.
Lifestyle measures (especially salt restriction) reduce attack burden, and the DVLA notification requirement is a frequently-tested, medico-legally important counselling point. The unpredictability and hearing loss of Ménière’s carry a high psychological burden, so mental-health and peer support are integral to care.
8
Treat

Long-Term Course & Complications

Natural history
Attacks typically cluster then remit; vertigo often “burns out” over years, but hearing loss tends to progress and become permanent.
Bilateral disease
Develops in a minority — has greater impact on hearing and balance; consider autoimmune workup.
Drop attacks (Tumarkin)
Sudden falls without warning → high injury risk; urgent ENT, may warrant ablative therapy.
Hearing rehabilitation
Hearing aids; cochlear implant in selected severe cases.
Mental health
High rates of anxiety/depression — proactive screening and support.
Comorbid vestibular migraine
Common overlap; treating migraine can substantially reduce symptom burden.
Understanding the natural history — vertigo often remitting while hearing loss progresses — frames realistic counselling and the timing of hearing rehabilitation. Tumarkin drop attacks are a dangerous complication warranting urgent specialist input, and recognising comorbid vestibular migraine can markedly improve outcomes.
9
Safety

Follow-Up & Safety-Netting

Regular review
Attack frequency/severity, hearing (serial audiometry via ENT), medication response and side effects, mood.
Prophylaxis review
Assess betahistine/lifestyle benefit at 3–6 months; escalate to ENT if disabling attacks persist.
Re-examine if features change
New asymmetrical/progressive hearing loss → MRI to exclude schwannoma; central signs → urgent reassessment.
Safety-net — same-day
Sudden hearing loss, vesicles/facial palsy, or new focal neurology → emergency ENT/stroke pathway.
DVLA & safety
Reinforce driving advice and occupational safety at each review.
Psychological
Screen for and treat anxiety/depression; signpost support.
Ongoing review tracks both the vestibular and the (often progressive) auditory components, and keeps the diagnosis under scrutiny — new asymmetrical or progressive hearing loss should still trigger MRI. Repeated reinforcement of DVLA and safety advice protects patients and others during unpredictable attacks.
Educational use only. Pathway based on: NICE CKS Ménière’s disease, AAO-HNS / Bárány Society diagnostic criteria, British Association of Otorhinolaryngology guidance, DVLA Assessing Fitness to Drive. See also the Vertigo and Hearing Loss pathways. Always adapt to individual patient context and local services.